

Contents

Contributing Authors	ix
Foreword	xvii
Preface	xix
Acknowledgments	xxi

Section I: Prediction of Drug Interactions From *In Vitro* Studies: Basic Principles

1 Metabolically-Based Drug–Drug Interactions: Principles and Mechanisms	3
<i>Kenneth E. Thummel, Kent L. Kunze, and Danny D. Shen</i>	
2 From <i>In Vitro</i> to <i>In Vivo</i> : An Academic Perspective	21
<i>René H. Levy and William F. Trager</i>	
3 Industrial Viewpoint: Application of <i>In Vitro</i> Drug Metabolism in Various Phases of Drug Development	29
<i>Barbara J. Ring and Steven A. Wrighton</i>	
4 Regulatory Viewpoint: Prediction of Drug Interactions from <i>In Vitro</i> Studies	41
<i>Jerry M. Collins</i>	

Section II: Enzymes and Transporters

5 Cytochromes P450: Historical Overview	51
<i>John B. Schenkman</i>	
6 CYP1A	61
<i>John O. Miners and Ross A. McKinnon</i>	
7 CYP2C	75
<i>Allan E. Rettie, Dennis R. Koop, and Robert L. Haining</i>	
8 CYP2D6	87
<i>Ulrich M. Zanger and Michel Eichelbaum</i>	
9 CYP2E1	95
<i>Judy Raucy and Susan P. Carpenter</i>	
10 CYP3A	115
<i>Steven A. Wrighton and Kenneth E. Thummel</i>	
11 P-Glycoprotein	135
<i>Jeffrey A. Silverman</i>	

12	Other CYP: 2A6, 2B6, 4A	145
	<i>Michael P. Pritchard and C. Roland Wolf</i>	
13	UDP-Glucuronosyltransferases	161
	<i>Thomas R. Tephly and Mitchell D. Green</i>	
14	Glutathione S-Transferases	175
	<i>David L. Eaton and Theo K. Bammler</i>	
15	Sulfotransferases and Methyltransferases	191
	<i>Richard M. Weinshilboum and Rebecca B. Raftogianis</i>	
16	Epoxide Hydrolases	205
	<i>Curtis J. Omiecinski</i>	

Section III: Drugs As Substrates of Metabolic Enzymes Treatment of CNS Diseases

17	Anticonvulsants	217
	<i>Gary G. Mather and René H. Levy</i>	
18	Antidepressants	233
	<i>Kan Chiba and Kaoru Kobayashi</i>	
19	Antipsychotics	245
	<i>C. Lindsay DeVane and John S. Markowitz</i>	
20	Sedative-Hypnotic and Anxiolytic Agents	259
	<i>David J. Greenblatt and Lisa L. von Moltke</i>	
21	Volatile, Intravenous, and Local Anesthetics	271
	<i>Evan D. Kharasch and Andra E. Ibrahim</i>	
22	Opioid Analgesics	297
	<i>Evan D. Kharasch</i>	
23	Agents for the Treatment of Migraine, Parkinson's, and Alzheimer's Diseases	321
	<i>Tina M. deVries and S. Thomas Forgue</i>	

Treatment of Cardiovascular Diseases

24	Calcium Channel Blockers	333
	<i>David R. Jones and Stephen D. Hall</i>	
25	β -Adrenoreceptor Antagonists	347
	<i>Martin S. Lennard</i>	
26	Angiotensin II Antagonists, ACE Inhibitors, and Diuretics	359
	<i>Michael Goldberg</i>	
27	Cholesterol-Lowering Agents and Cardiac Glycosides	379
	<i>Yves Horsmans</i>	
28	Antiarrhythmics	391
	<i>Martin F. Fromm and Michel Eichelbaum</i>	
29	Oral Anticoagulants	403
	<i>William F. Trager</i>	

Treatment of Microbial Diseases

- 30** Oral Antifungals 415
David J. Edwards
- 31** Antivirals 421
Jashvant D. Unadkat and Yi Wang

Treatment of Inflammation

- 32** H₁-Receptor Antagonists 435
Danny D. Shen, Soraya Madani, Christopher Banfield, and Robert P. Clement
- 33** Analgesics–Antipyretics 447
Sidney D. Nelson
- 34** Nonsteroidal Antiinflammatory Drugs 457
Timothy S. Tracy
- 35** Methylxanthines 469
Donald J. Birkett and John O. Miners

Treatment of Other Diseases

- 36** H₂-Antagonists, Proton-Pump Inhibitors, and Antiemetics 483
Ronald M. Laethem and Cosette J. Serabjit-Singh
- 37** Immunosuppressive Agents 499
Mary F. Hebert
- 38** Estrogens and Progestins 511
Maurice G. Emery
- 39** Hypoglycemic Agents 529
William R. Brian
- 40** Antineoplastic Agents 545
James B. Mangold and Volker Fischer

Section IV: Drugs as Inhibitors of Metabolic Enzymes**Treatment of CNS Diseases**

- 41** Anticonvulsants 557
René H. Levy, Gary G. Mather, and Gail D. Anderson
- 42** Antidepressants 563
Mujeeb U. Shad and Sheldon H. Preskorn
- 43** Neuroleptics and Antipsychotics 579
Michael Murray

Treatment of Cardiovascular Diseases

- 44** Calcium Channel Blockers 591
Dagmar Busse and Michel Eichelbaum

45	Antiarrhythmics	603
	<i>Kim Brøsen</i>	
Treatment of Microbial Diseases		
46	Antimicrobials and Antiparasitics	615
	<i>Ronald E. Polk</i>	
47	Antifungals	623
	<i>Janne T. Backman, Kari T. Kivistö, Jun-Sheng Wang, and Pertti J. Neuvonen</i>	
48	Protease Inhibitors	647
	<i>Jashvant D. Unadkat and Yi Wang</i>	
Treatment of Other Diseases		
49	H ₂ -Receptor Antagonists	653
	<i>Mary F. Paine</i>	
50	Inhibitors in the Diet: Grapefruit Juice–Drug Interactions	661
	<i>David G. Bailey, J. Malcolm O. Arnold, and J. David Spence</i>	
Section V: Drugs as Inducers of Metabolic Enzymes		
51	Phenobarbital, Phenytoin, and Carbamazepine	673
	<i>Susan M. Abdel-Rahman and J. Steven Leeder</i>	
52	Rifampin, Dexamethasone, and Omeprazole	691
	<i>Graham R. Jang and Patrick J. P. Maurel</i>	
53	Isoniazid and Ethanol	707
	<i>John T. Slattery</i>	
Section VI: Clinical Considerations		
54	Clinical and Pharmacoeconomic Significance of Metabolic Drug Interactions	715
	<i>Philip D. Hansten</i>	
55	Pharmacist Management of Drug Interactions	723
	<i>Philip D. Hansten</i>	
56	Interactions in the Elderly	729
	<i>Robert E. Vestal and Barry J. Cusack</i>	
Section VII: Appendix		
	Other Drugs	745
	<i>Kenneth E. Thummel and René H. Levy</i>	
	Drug Interaction Index	749
	General Index	765